Garg Strikes Back: Opposition Filed and New Delaware Suit Challenges Poison Pill
BETR is trading near its 52-week low of $11.111 (7.9% above the low) on elevated volume (1.9× avg).
Summary
Vishal Garg filed an opposition to Better's injunction request and a new Delaware lawsuit to invalidate the poison pill, while the Company filed an Amended Complaint detailing alleged securities law violations. The filing also reveals the Board offered Garg a $15M+ advisory role three days after terminating him.
Key Events · Legal and Risk Events · BETR
-
Garg Opposes Injunction, Files Delaware Suit
On August 25, Garg filed an opposition to Better's request for immediate injunctive relief, arguing the lawsuit is part of a plan by interim CEO Daniel Lewis to entrench himself and the current Board. He also filed a separate Delaware Chancery Court action seeking to invalidate the poison pill, alleging the Board breached fiduciary duties by adopting it for pretextual reasons.
-
Board Offered Garg $15M+ Advisory Package
The filing discloses that three days after terminating Garg on August 3, the Board offered him a Vice Chairman and advisor role including $750,000 annually in cash and 875,000 shares valued at more than $15 million at the time — a fact Garg argues contradicts the Board's stated rationale for his removal.
-
Stock Plunged 41.6% After Garg's Removal
Better's stock fell 41.6% the trading day after Garg's removal and had declined by nearly 60% as of August 21, 2026, according to the filing.
-
Company Files Amended Complaint
On August 24, Better filed an Amended Complaint in SDNY adding detailed allegations, including claims that Garg overstated his voting power by 1,161,411 votes by counting 387,137 unexercised stock options as voting shares, and that he attempted to vote those options on August 14.
Analysis · BETR · Finance
The proxy war between Better Home & Finance and founder Vishal Garg escalated sharply on August 25. Garg filed an opposition to the Company's injunction request, arguing the lawsuit is a pretext by interim CEO Daniel Lewis to entrench the current Board. He also launched a separate Delaware Chancery Court action seeking to invalidate the poison pill, claiming the Board breached fiduciary duties by adopting it to thwart shareholder voting rights. The filing reveals the Board offered Garg a $15M+ advisory package three days after firing him — a fact that undercuts the Company's narrative that Garg was removed for cause. With Garg's Amended Proxy Statement set to become effective as early as August 27, the outcome of these legal battles will determine whether shareholders get to vote on removing five directors and reinstating Garg as CEO.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BETR was trading at $11.99 on NASDAQ in the Finance sector, with a market capitalization of approximately $233.7M. The 52-week trading range was $11.11 to $94.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.